[SMLE] Lambert-Eaton Myasthenic Syndrome Recurrence Induced by Pembrolizumab in a Patient with Non-small-cell Lung Cance
Posté : 01 sept. 2022 12:00
Intern Med. 2022 Aug 30. doi: 10.2169/internalmedicine.0072-22. Online ahead of print.
ABSTRACT
A 73-year-old woman in complete remission from localized small-cell lung cancer associated with Lambert-Eaton myasthenic syndrome (LEMS) 22 years earlier was referred to our hospital and diagnosed with non-small-cell lung cancer. After three courses of pembrolizumab, an immune checkpoint inhibitor, the patient complained of muscle weakness, fatigue, ptosis, and dysarthria. The anti-voltage-gated calcium channel antibody level was elevated, and waxing was observed on a high-frequency repetitive stimulation test using an electromyogram. We diagnosed her with recurrence of LEMS as an immune-related adverse event (irAE) induced by pembrolizumab. After intravenous immunoglobulin therapy, the patient's symptoms improved, and she was discharged.
PMID:36047125 | DOI:10.2169/internalmedicine.0072-22
Source: https://pubmed.ncbi.nlm.nih.gov/3604712 ... 1&v=2.17.7